CN1486969A - Composite mineral salf of potassium-magnesium hydrogen citrate and its prepn process - Google Patents
Composite mineral salf of potassium-magnesium hydrogen citrate and its prepn process Download PDFInfo
- Publication number
- CN1486969A CN1486969A CNA031323057A CN03132305A CN1486969A CN 1486969 A CN1486969 A CN 1486969A CN A031323057 A CNA031323057 A CN A031323057A CN 03132305 A CN03132305 A CN 03132305A CN 1486969 A CN1486969 A CN 1486969A
- Authority
- CN
- China
- Prior art keywords
- potassium
- magnesium
- hydrogen citrate
- calculus
- magnesium hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to composite mineral salt of potassium-magnesium hydrogen citrate and its preparation process. The potassium-magnesium hydrogen citrate is prepared through mixing citric acid and water, and reaction with potassium compound and magnesium compound at the temperature below 100 deg.c with the molar ratio between Mg, K, H and citric acid being 1 to 3 to 1 to 2. The composite salt of potassium-magnesium hydrogen citrate has obvious curative effect on urinary calculus, owing to the citrate radical ion and magnesium ion to suppress calcium-containing calculus crystallization, magenesium ion to lower the concentration of calculus forming matter in urine and capable of combining with oxalic acid to form magnesium oxalate to exhaust together with urine. The composite salt can raise pH value of urine and dissolve uric acid calculus and cystine calculus directly without causing adverse reaction.
Description
Technical Field
The invention relates to a composite mineral salt, in particular to a potassium magnesium hydrogen citrate composite mineral salt and a preparation method thereof.
Background
Before the invention is made, the medicines for clinically treating urolithiasis mainly comprise potassium citrate and calculus removing medicinal granules. Patients are easy to cause hyperkalemia after using the potassium citrate, and the curative effect is not comprehensive; the granule for removing calculus can not dissolve calculus strictly, and the caulis Akebiae component contains nephrotoxic aristolochic acid, which has great harm to renal tubule. The prevalence rate of the population suffering from urolithiasis can reach 5%, the recurrence rate is high, 15% in one year and 50% in ten years, and the main consequences of urolithiasis are hydronephrosis and urinary tract infection, which may finally cause renal function damage. Therefore, there is a clinical lack of effective drugs for treating urinary calculi.
Disclosure of Invention
The invention aims to overcome the defects and develop the potassium magnesium hydrogen citrate composite salt capable of effectively treating urolithiasis and the preparation method thereof.
The technical scheme of the invention is as follows:
the composite mineral salt of potassium-magnesium hydrogen citrate is mainly technically characterized in that a compound contains magnesium, potassium and citric acid, and the synthetic reaction formula is as follows:
the structural formula of the product is as follows:
the molar ratio of the four ions is magnesium, potassium, hydrogen and citric acid is 1: 3: 1: 2.
The invention also adopts the technical scheme that: the preparation method of the potassium magnesium hydrogen citrate composite mineral salt is characterized by comprising the following steps:
(4) mixing citric acid with water, and stirring;
(5) adding a potassium compound and a magnesium compound;
(6) controlling the reaction temperature below 100 ℃ when adding the magnesium compound;
the invention has the advantages and effects that: approximately 90% of urinary calculi are calcium-containing calculi, the main components of which are calcium oxalate and calcium phosphate crystals, and citrate ions and magnesium ions are inhibiting factors of the calcium-containing calculi crystals; the potassium magnesium hydrogen citrate can dissociate citrate ions and magnesium ions in human urine, not only can directly inhibit the formation of calcium-containing calculus crystals, but also can reduce the concentration of calculus-forming substances in urine through complexation, thereby indirectly inhibiting the formation of calculus; in particular, citrate ions can be synthesized into soluble calcium citrate with a calcium complex in urine to reduce the concentration of calcium ions in urine, magnesium ions can be combined with oxalic acid in urine to form soluble magnesium oxalate which is discharged with urine to reduce the concentration of oxalic acid in urine; in addition, the potassium magnesium hydrogen citrate is an alkaline substance, can improve the pH value of urine, and directly dissolves uric acid calculus and cystine calculus, and the calculus accounts for about 5% of urinary calculus; the potassium magnesium hydrogen citrate dissociates in human urine to form various ions which belong to human physiological substances, and has no adverse reaction under the conventional dosage.
Detailed Description
Example 1:
mixing 120g citric acid and 30g water in a tank, stirring rapidly, adding 12.6g magnesium oxide, introducing CO2In the case of (3), 64.8g of potassium carbonate was added in four equal portions, and finally 10g of water was added to complete the reaction; the reaction temperature is controlled below 100 ℃ and exceeds 120 ℃, the product is easy to degenerate, and the optimum temperature is controlled at 80 ℃; after drying, the density is determined to be greater than 1.1g/mm3Can be made into tablet. Each tablet contains 1.75mmol of magnesium, 5.25mmol of potassium and 3.5mmol of citric acid.
Example 2:
48.03kg of citric acid and 12kg of water were mixed in a 7 gallon ribbon blender for about 2 minutes and 5.04kg of MgO was added in three equal portions (each with continuous stirring for 3 minutes) with the same temperature control as in example 1; then 51.8kgK2CO3Adding the mixture in three parts (each part is continuously stirred for 5 minutes); finally, 4kg of water is added, mixed for 2-5 minutes, the product is filtered and dried for 3 hours at the temperature of 60 ℃, and the density of the product (particles) is more than 1.1g/mm3. Pulverizing to pharmaceutical grade for pharmaceutical use.
Mixing dried magnesium potassium hydrogen citrate with 1% (by weight) magnesium stearate, and tabletting for multiple times to obtain tablet; each tablet contains 42mg magnesium, 205.5mg potassium and 662mg citric acid.
Example 3:
with MgCO3Replacing MgO, and making into product with density of more than 1.0g/mm3Potassium magnesium hydrogen citrate.
Example 4:
with Mg (OH)2Replacing MgO, and making into product with density of more than 1.0/mm3Potassium magnesium hydrogen citrate.
The potassium magnesium hydrogen citrate has good molar ratio and can be prepared into enteric-coated tablets.
The density of the wax-free sheet is 1.6g/mm3The density of wax flakes is 1.4g/mm3。
Coating with sucrose, polyvidone, calcium carbonate, etc.
The ideal weight ratio of the potassium magnesium hydrogen citrate tablet is as follows:
magnesium, potassium, hydrogen and citric acid are 4.8: 23: 0.2: 72.
The water content of the water-containing mixture is controlled at 10-20%. If the water content is lower than 10%, the reaction is not completely carried out; if the water content is more than 20%, a paste is generated, and the reaction time is prolonged.
In the present invention, 3.5mmol (893mg) of potassium magnesium hydrogen citrate contains 1.75mmol of magnesium, 5.25mmol of potassium, 1.751mmol of hydrogen and 3.5mmol of citric acid.
Claims (7)
1. The potassium magnesium hydrogen citrate composite mineral salt is characterized by containing potassium, magnesium and citric acid, and the synthetic reaction formula is as follows:
the molar ratio of the four ions is magnesium, potassium, hydrogen and citric acid is 1: 3: 1: 2.
2. The preparation method of the potassium magnesium hydrogen citrate composite mineral salt is characterized by comprising the following steps:
(1) mixing citric acid with water, and stirring;
(2) adding a potassium compound and a magnesium compound;
(3) when the magnesium compound is added, the reaction temperature is controlled below 100 ℃.
3. The process for preparing potassium magnesium hydrogen citrate as claimed in claim 2, wherein the reaction temperature in the step (3) is controlled to 80 ℃.
4. The process for preparing potassium magnesium hydrogen citrate as claimed in claim 2, wherein the water content of the final product is controlled to 10-20%.
5. The process of claim 2 wherein the potassium compound is KHCO3、K2CO3。
6. The process for preparing potassium magnesium hydrogen citrate as claimed in claim 2, wherein the magnesium compound is MgCO3、MgO、Mg(OH)2。
7. The process of claim 2 wherein the resultant product is agitated in a ribbon blender to form granules, dried to form potassium magnesium hydrogen citrate granules, and crushed to pharmaceutical grade for pharmaceutical use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031323057A CN1486969A (en) | 2003-08-13 | 2003-08-13 | Composite mineral salf of potassium-magnesium hydrogen citrate and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031323057A CN1486969A (en) | 2003-08-13 | 2003-08-13 | Composite mineral salf of potassium-magnesium hydrogen citrate and its prepn process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1486969A true CN1486969A (en) | 2004-04-07 |
Family
ID=34154095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031323057A Pending CN1486969A (en) | 2003-08-13 | 2003-08-13 | Composite mineral salf of potassium-magnesium hydrogen citrate and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1486969A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1722772A4 (en) * | 2004-03-08 | 2008-03-19 | Mission Pharma Co | Dietary supplementation with stoichiometrically specific potassium magnesium citrate |
| CN102557921A (en) * | 2011-12-28 | 2012-07-11 | 合肥科尚医药科技有限公司 | Preparation method of potassium sodium hydrogen citrate complex salt hydrate |
| CN109529107A (en) * | 2018-12-07 | 2019-03-29 | 中鼎凯瑞科技成都有限公司 | The organic and inorganic spontaneous coagulation composite bone graft object that multiple trace element organic compound and inorganic compound are formed by hydration bridgeization |
-
2003
- 2003-08-13 CN CNA031323057A patent/CN1486969A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1722772A4 (en) * | 2004-03-08 | 2008-03-19 | Mission Pharma Co | Dietary supplementation with stoichiometrically specific potassium magnesium citrate |
| CN102557921A (en) * | 2011-12-28 | 2012-07-11 | 合肥科尚医药科技有限公司 | Preparation method of potassium sodium hydrogen citrate complex salt hydrate |
| CN109529107A (en) * | 2018-12-07 | 2019-03-29 | 中鼎凯瑞科技成都有限公司 | The organic and inorganic spontaneous coagulation composite bone graft object that multiple trace element organic compound and inorganic compound are formed by hydration bridgeization |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2619591C (en) | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same | |
| AU2004213819A1 (en) | Ferric organic compounds, uses thereof and methods of making same | |
| CN102143742B (en) | Phosphate binding materials and their uses | |
| CN101128206A (en) | Tetracycline metal complex in a solid dosage form | |
| IE48879B1 (en) | An analgesic effervescent powder and process for its preparation | |
| US5219889A (en) | Dietary supplementation with potassium magnesium citrate | |
| CN1486969A (en) | Composite mineral salf of potassium-magnesium hydrogen citrate and its prepn process | |
| FR2563108A1 (en) | ANTIACID PHARMACEUTICAL COMPOSITION AND AQUEOUS SUSPENSION CONTAINING THE SAME | |
| NZ544826A (en) | A doxycycline metal complex in a solid dosage form | |
| JP3189044B2 (en) | Calcium preparations, raw materials therefor and methods for their production | |
| WO1991004737A1 (en) | Osteogenesis promoter | |
| WO1996038058A1 (en) | Composition containing readily absorbable calcium and process for producing the same | |
| US20060063832A1 (en) | Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof | |
| KR100750727B1 (en) | Composition and formulation containing chitosan | |
| CN1233663C (en) | Preparation of carboxymethyl chitin bismuth and its application in treating gastritis and gastrelcoma | |
| JP3131385B2 (en) | Composition containing easily absorbable calcium and method for producing the same | |
| CN101062418A (en) | Cyclodextrin inclusion compound of entecavir, the preparing method and the medicine combination including the same | |
| JPH02206A (en) | Novel drug preparation containing exifone and water-soluble polymeric compound | |
| EP0429157A2 (en) | Dietary supplementation with potassium magnesium citrate | |
| CN107397810B (en) | Iron hydroxide-peach gum-based phosphorus binder, preparation method and application thereof | |
| JPH0251527B2 (en) | ||
| JPS59176212A (en) | Aqueous solution dispersion of chlorosalidone | |
| CN1214796C (en) | Method for preparing slow release micro pill of aspirin | |
| WO1988003023A1 (en) | Drug composition for treating liver diseases and process for its preparation | |
| WO2008000463A2 (en) | Rabeprazole formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |